Cargando…
Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma
Drug resistance and dose-limiting toxicities are significant barriers for treatment of multiple myeloma (MM). Bone marrow microenvironment (BMME) plays a major role in drug resistance in MM. Drug delivery with targeted nanoparticles have been shown to improve specificity and efficacy and reduce toxi...
Autores principales: | Federico, Cinzia, Alhallak, Kinan, Sun, Jennifer, Duncan, Kathleen, Azab, Feda, Sudlow, Gail P., de la Puente, Pilar, Muz, Barbara, Kapoor, Vaishali, Zhang, Luna, Yuan, Fangzheng, Markovic, Matea, Kotsybar, Joseph, Wasden, Katherine, Guenthner, Nicole, Gurley, Shannon, King, Justin, Kohnen, Daniel, Salama, Noha N., Thotala, Dinesh, Hallahan, Dennis E., Vij, Ravi, DiPersio, John F., Achilefu, Samuel, Azab, Abdel Kareem |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699624/ https://www.ncbi.nlm.nih.gov/pubmed/33247158 http://dx.doi.org/10.1038/s41467-020-19932-1 |
Ejemplares similares
-
Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
por: Sun, Jennifer, et al.
Publicado: (2020) -
Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy
por: Alhallak, Kinan, et al.
Publicado: (2021) -
A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma
por: Alhallak, Kinan, et al.
Publicado: (2021) -
Liposomal phytohemagglutinin: In vivo T‐cell activator as a novel pan‐cancer immunotherapy
por: Alhallak, Kinan, et al.
Publicado: (2022) -
Nanoparticle T cell engagers for the treatment of acute myeloid leukemia
por: Alhallak, Kinan, et al.
Publicado: (2021)